ES2044829T1 - Una composicion para el tratamiento in vivo de da\os en los tejidos producidos por isquemia u otra disfuncion proveniente de oxidacion. - Google Patents

Una composicion para el tratamiento in vivo de da\os en los tejidos producidos por isquemia u otra disfuncion proveniente de oxidacion.

Info

Publication number
ES2044829T1
ES2044829T1 ES90915877T ES90915877T ES2044829T1 ES 2044829 T1 ES2044829 T1 ES 2044829T1 ES 90915877 T ES90915877 T ES 90915877T ES 90915877 T ES90915877 T ES 90915877T ES 2044829 T1 ES2044829 T1 ES 2044829T1
Authority
ES
Spain
Prior art keywords
damage
treatment
ischemia
compositions
attacks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES90915877T
Other languages
English (en)
Other versions
ES2044829T3 (es
Inventor
John M Carney
Robert A Floyd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
University of Kentucky Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
University of Kentucky Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/422,651 external-priority patent/US5025032A/en
Application filed by Oklahoma Medical Research Foundation, University of Kentucky Research Foundation filed Critical Oklahoma Medical Research Foundation
Publication of ES2044829T1 publication Critical patent/ES2044829T1/es
Application granted granted Critical
Publication of ES2044829T3 publication Critical patent/ES2044829T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DESCRIBEN COMPOSICIONES CONTENIENDO COMO INGREDIENTE ACTIVO UN REACTIVO QUE ES ATRAPADO EN EL CENTRIFUGADO, PREFERENTEMENTE (ALFA)-FENIL BUTIL NITRONA (PNB), O SUS DERIVADOS QUE SON ATRAPADOS EN EL CENTRIFUGADO, EN UN PORTADOR FARMACEUTICO APROPIADO PARA LA ADMINISTRACION A UN PACIENTE, PARA EL TRATAMIENTO O PREVENCION DE SINTOMAS ASOCIADOS CON ATAQUES U OTROS DAÑOS ISQUEMICOS, ENVEJECIMIENTO U OTRAS CONDICIONES ASOCIADAS CON EL DAÑO OXIDATIVO A LOS TEJIDOS. PARA LA PREVENCION O TRATAMIENTO DEL DAÑO COMO RESULTADO DE LA ISQUEMIA, LAS COMPOSICIONES SE ADMINISTRAN ANTES O DURANTE LA ISQUEMIA EN UNA DOSIS EFICAZ, PARA PREVENIR O INVERTIR LA PREDISPOSICION DE LAS CELULAS AL DAÑO RESULTANTE DEL EMPOBRECIMIENTO DE ATP Y EL DAÑO DE LA GENERACION DE RADICAL LIBRE QUE SIGUE A LA REPERCUSION. EJEMPLOS DE ENFERMEDADES QUE PUEDEN SER TRATADAS INCLUYEN; ATAQUES, MENINGITIS, PERDIDA NEURONAL PROGRESIVA DEBIDO A LA ENFERMEDAD DE PARKINSON, DEMENCIA SENIL, DROGADICCION, ENFERMEDADES QUE APARECEN POR LAEXPOSICION A OXIGENO A GRAN PRESION O ENTORNOS CON OXIGENO ENRIQUECIDO, Y UNA HEMORRAGIA DEL TEJIDO NERVIOSO COMO RESULTADO DE UN TRAUMATISMO. PARA EL TRATAMIENTO DEL ENVEJECIMIENTO, LAS COMPOSICIONES SE ADMINISTRAN PREFERENTEMENTE UNA O DOS VECES AL DIA MEDIANTE ADMINISTRACION ORAL DURANTE UN PERIODO DE DOS SEMANAS. SE OBSERVA UNA SIGNIFICANTE REDUCCION DE PROTEINAS OXIDADAS Y RECUPERACION DE MEMORIA AL CABO DE SIETE DIAS DESPUES DEL COMIENZO DEL TRATAMIENTO.
ES90915877T 1989-10-17 1990-10-17 Metodo y composiciones para la inhibicion de alteraciones asociadas con las lesiones oxidativas de los tejidos. Expired - Lifetime ES2044829T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/422,651 US5025032A (en) 1989-10-17 1989-10-17 Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage
US58917790A 1990-09-27 1990-09-27

Publications (2)

Publication Number Publication Date
ES2044829T1 true ES2044829T1 (es) 1994-01-16
ES2044829T3 ES2044829T3 (es) 1995-01-16

Family

ID=27025701

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90915877T Expired - Lifetime ES2044829T3 (es) 1989-10-17 1990-10-17 Metodo y composiciones para la inhibicion de alteraciones asociadas con las lesiones oxidativas de los tejidos.

Country Status (12)

Country Link
US (4) US5405874A (es)
EP (1) EP0496796B1 (es)
JP (5) JP2620413B2 (es)
KR (1) KR960008230B1 (es)
AT (1) ATE110565T1 (es)
AU (4) AU653921B2 (es)
CA (1) CA2069961C (es)
DE (1) DE69012138T2 (es)
DK (1) DK0496796T3 (es)
ES (1) ES2044829T3 (es)
HK (1) HK1007281A1 (es)
WO (1) WO1991005552A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2395803A1 (es) * 2011-08-01 2013-02-15 Consejo Superior De Investigaciones Científicas (Csic) - 80% Quinolilnitronas

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991005552A1 (en) * 1989-10-17 1991-05-02 Oklahoma Medical Research Foundation Method and compositions for inhibition of disorders associated with oxidative damage
US5681845A (en) * 1989-10-17 1997-10-28 Oklahoma Medical Research Foundation DMPO spin trapping compositions and methods of use thereof
US20050107366A1 (en) * 1991-06-18 2005-05-19 Carney John M. Spin trapping pharmaceutical compositions and methods for use thereof
US6002001A (en) 1991-06-18 1999-12-14 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
DE69232263T2 (de) * 1991-06-18 2003-06-18 Oklahoma Medical Research Foundation, Oklahoma Radikalfänger ("spin traps") zur behandlung von mit oxidation von lipiden und proteinen verbundenen erkrankungen
AU652662B2 (en) * 1991-09-12 1994-09-01 Aventis Inc. Cyclic nitrones
US5292746A (en) * 1991-09-12 1994-03-08 Merrell Dow Pharmaceuticals Inc. Cyclic nitrones, pharmaceutical compositions thereof and their use in treating shock
JPH0656669A (ja) * 1992-06-11 1994-03-01 Asahi Breweries Ltd 活性酸素消去作用を持つプテリン誘導体製剤
JPH08505406A (ja) * 1993-10-25 1996-06-11 オゥクラホゥマ、メディカル、リサーチ、ファウンデイシャン 新規のリン含有スピン捕捉組成物
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
FR2731428B1 (fr) * 1995-03-06 1997-06-06 Centre Nat Rech Scient Derives phosphoryles de nitrones, leur procede de preparation et compositions les contenant
JPH11512427A (ja) * 1995-09-11 1999-10-26 ヘキスト・マリオン・ルセル・インコーポレイテツド 環状ニトロンおよびこれらを含有する医薬組成物
WO1997019054A1 (en) * 1995-11-17 1997-05-29 Florida International University Azulenyl nitrone spin trapping agents, methods of making and using same
NZ332315A (en) * 1996-04-17 2000-03-27 Centaur Pharmaceuticals Inc Nitrone free radical trapping compounds and their use in the treatment of dementia associated with aids virus (HIV-1) infection
JP2000509375A (ja) * 1996-04-23 2000-07-25 センター ファーマシューティカルズ，インコーポレイテッド 眼炎症の処置における使用のためのニトロン化合物を含む組成物
US5900227A (en) * 1996-06-17 1999-05-04 Oklahoma Medical Research Foundation Multicyclic nitrone spin trapping compositions
IL128070A0 (en) * 1996-07-19 1999-11-30 Centaur Pharmaceuticals Inc Furan nitrone compounds
TW429241B (en) 1996-09-26 2001-04-11 Sumitomo Pharma Nitrone derivatives
MA26553A1 (fr) 1997-10-17 2004-12-20 Centaur Pharmaceuticals Inc Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la
CN1136212C (zh) * 1998-01-16 2004-01-28 桑道药品有限公司 噻吩硝酮化合物
NZ505757A (en) * 1998-01-16 2002-09-27 Centaur Pharmaceuticals Inc Thioether furan nitrone compounds and pharmaceuticals thereof; useful for the treatment or prophylaxis of neurodegenerative, autoimmune and inflammatory conditions
RU2225392C2 (ru) * 1998-06-24 2004-03-10 Реновис, Инк. Альфа-арил-N-алкилнитроны, фармацевтические композиции (варианты), способ ингибирования нейродегенеративных заболеваний, способ лечения и способы профилактики (варианты)
JP2002520386A (ja) 1998-07-17 2002-07-09 セントアー ファーマシューティカルズ インコーポレイテッド 炎症を処置するためのα−（２−ヒドロキシフェニル）ニトロン化合物、α−（２−ヒドロキシフェニル）ニトロン化合物を含む薬学的組成物およびそれらの使用
US6730700B2 (en) 1998-12-02 2004-05-04 Renovis, Inc. 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
UA66401C2 (en) * 1998-12-02 2004-05-17 Sentor Pharmaceuticals Inc 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical composition containing the same
US6339102B1 (en) * 1999-06-09 2002-01-15 The United States Of America As Represented By The Secretary Of The Army Method and composition for treating and preventing retinal damage
US6569902B2 (en) * 2000-03-30 2003-05-27 Oklahoma Medical Research Foundation Nitrone inhibition of cancer development
SE0001916D0 (sv) * 2000-05-23 2000-05-23 Astrazeneca Ab Novel formulation
AU2002253857A1 (en) 2001-01-08 2002-09-04 Centaur Pharmaceuticals, Inc. Use of aryl nitrone compounds in methods for treating neuropathic pain
US20030045461A1 (en) * 2001-09-06 2003-03-06 Jen-Chang Hsia Composition and methods of esterified nitroxides gated with carboxylic acids
FR2846968B1 (fr) 2002-11-08 2005-02-04 Salles Jean Pierre Nouveaux derives amphiphiles de l'alpha-c-phenyl-n-tert- butyl nitrone
US6762322B1 (en) * 2002-12-20 2004-07-13 Goodyear Tire & Rubber Company Preparation of nitrone derivatives
US20050059638A1 (en) * 2003-08-04 2005-03-17 Kelly Michael G. Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
US20050182060A1 (en) * 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
US20060235370A1 (en) * 2005-04-04 2006-10-19 Oblong John E Method of regulating mammalian keratinous tissue
US7125934B1 (en) * 2005-06-28 2006-10-24 The Goodyear Tire & Rubber Company Functionalization of living rubbery polymers with nitrones
AU2007277193B2 (en) * 2006-07-25 2013-06-13 Hough Ear Institute Methods for treating acute acoustic trauma
EP2242360B1 (en) * 2008-02-12 2015-04-08 Tosk, Inc. Doxorubicin adjuvants to reduce toxicity and methods for using the same
JP5253494B2 (ja) * 2008-03-07 2013-07-31 国立大学法人 熊本大学 電子スピン共鳴測定用試料溶液及びその乾固物，並びにそれらを用いた測定方法
BRPI1013739A2 (pt) * 2009-04-20 2016-04-05 Volvo Constr Equip Ab sistema e método de pavimentação integrados.
US9034926B2 (en) 2010-12-30 2015-05-19 Nicholas V. Perricone Topical nitrone spin trap compositions for psoriasis
US8986739B2 (en) 2011-02-28 2015-03-24 Nicholas V. Perricone Treatment of urinary incontinence using nitrone spin traps
DE102011088787A1 (de) 2011-12-16 2013-06-20 Evonik Industries Ag Siloxannitrone und deren Anwendung
WO2022169642A1 (en) * 2021-02-08 2022-08-11 Oklahoma Medical Research Foundation Okn-007 as a therapeutic agent for neurodegenerative diseases
DE102023124443A1 (de) * 2023-09-11 2025-03-27 Albert-Ludwigs-Universität Freiburg, Körperschaft des öffentlichen Rechts Vorrichtung zur Modifikation von Blut

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE273702C (es) *
US35213A (en) * 1862-05-13 Improved hydrant
US35112A (en) * 1862-04-29 Improvement in head-rests for car-seats
US3396027A (en) * 1964-05-13 1968-08-06 Eastman Kodak Co Method of noodling gelatin dispersions
NL131665C (es) 1964-05-18
US3296145A (en) * 1965-10-21 1967-01-03 Millmaster Onyx Corp Quaternary ammonium-tertiary amine oxide compositions
US3775122A (en) * 1967-07-28 1973-11-27 American Can Co Image production using photosensitive compositions of nitrone which is heat developed
US3834073A (en) * 1971-05-03 1974-09-10 Scm Corp Phenyl nitrone derivatives useful as seed protectants
US3849934A (en) * 1971-05-03 1974-11-26 Scm Corp Alpha-aryl-n-lower alkyl nitrone-containing compositions useful as anti-fungal agents
US3767818A (en) * 1971-05-03 1973-10-23 Scm Corp Phenyl nitrone containing compositions useful as anti microbial agents
GB1531278A (en) * 1975-12-15 1978-11-08 Shionogi & Co 9,10-dihydro-9,10-methanoanthracene n-oxide derivatives and the production thereof
GB1588417A (en) * 1977-03-15 1981-04-23 Agfa Gevaert Photoresist materials
US4197314A (en) * 1977-10-06 1980-04-08 William H. Rorer, Inc. Method of treating inflammation
US4224340A (en) * 1977-10-06 1980-09-23 William H. Rorer, Inc. Anti-inflammatory compositions containing α-phenyl-N-phenylnitrone compounds
US4153722A (en) * 1977-10-06 1979-05-08 William H. Rorer, Inc. Method of treatment
US4214003A (en) * 1977-10-06 1980-07-22 William H. Rorer, Inc. Method of treatment
US4870002A (en) * 1981-04-07 1989-09-26 The United States Of America As Represented By The Secretary Of The Air Force Method of prevention of oxidative injury to cells
AU1107888A (en) * 1986-12-29 1988-07-27 Pharmacia Ab Nitroxide compounds for the preparation of a pharmaceutical composition intended for the prophylaxis and treatment of ischemic cell damage
AU1362488A (en) * 1987-01-28 1988-08-24 Peter H. Proctor Topical composition and method for stimulating hair growth with stable free radicals
WO1991005552A1 (en) * 1989-10-17 1991-05-02 Oklahoma Medical Research Foundation Method and compositions for inhibition of disorders associated with oxidative damage
USRE35213E (en) 1989-10-17 1996-04-16 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration
US5025032A (en) * 1989-10-17 1991-06-18 Oklahoma Medical Research Foundation Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2395803A1 (es) * 2011-08-01 2013-02-15 Consejo Superior De Investigaciones Científicas (Csic) - 80% Quinolilnitronas

Also Published As

Publication number Publication date
EP0496796A1 (en) 1992-08-05
DE69012138D1 (de) 1994-10-06
JPH10259178A (ja) 1998-09-29
WO1991005552A1 (en) 1991-05-02
DK0496796T3 (da) 1994-10-03
EP0496796B1 (en) 1994-08-31
KR920702220A (ko) 1992-09-03
US6107315A (en) 2000-08-22
US5405874A (en) 1995-04-11
JP2620413B2 (ja) 1997-06-11
JPH0925263A (ja) 1997-01-28
JPH05505792A (ja) 1993-08-26
AU710341B2 (en) 1999-09-16
DE69012138T2 (de) 1995-04-06
ES2044829T3 (es) 1995-01-16
JPH10259128A (ja) 1998-09-29
AU8310198A (en) 1998-12-24
JP2002179563A (ja) 2002-06-26
AU692197B2 (en) 1998-06-04
AU653921B2 (en) 1994-10-20
US5578617A (en) 1996-11-26
US5681965A (en) 1997-10-28
CA2069961C (en) 2000-05-02
JP2816326B2 (ja) 1998-10-27
HK1007281A1 (en) 1999-04-09
CA2069961A1 (en) 1991-04-18
JP2975587B2 (ja) 1999-11-10
AU6613390A (en) 1991-05-16
KR960008230B1 (ko) 1996-06-21
AU8310298A (en) 1998-10-22
ATE110565T1 (de) 1994-09-15
AU1131595A (en) 1995-03-23
AU710342B2 (en) 1999-09-16

Similar Documents

Publication Publication Date Title
ES2044829T1 (es) Una composicion para el tratamiento in vivo de da\os en los tejidos producidos por isquemia u otra disfuncion proveniente de oxidacion.
UY23835A1 (es) Procedimiento para la preparacion de compuesto de acilo
ES2086270T3 (es) Metabolitos de terfenadina y sus isomeros opticamente puros para tratar trastornos alergicos.
ES2040232T3 (es) Preparaciones medicinales para administracion oral conteniendo una sola dosis de 10 a 240 mg de dihidropiridina.
DE3876877D1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
IT1245761B (it) Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
ES2063011T3 (es) Agentes antibacteriales de quinolonas y naftiridinas que contienen un alfa-aminoacido en la cadena lateral del 7-sustituyente.
ATE31625T1 (de) Pharmazeutisches mittel zur behandlung des diabetes mellitus.
IT7849462A0 (it) Corpo di capsula in particolare per una capsula per la somministrazione di sostanze medicamentose come pure procedimento e dispositivo per lasua produzione
DK20488A (da) Farmaceutiske praeparater med forlaenget afgivelse
KR910009242A (ko) 치근막 질환 치료용 서방성 조성물
DE3774361D1 (de) Verwendung von usninsaeure oder deren derivaten bei der behandlung von zahnfaeule.
ES2001706A6 (es) Procedimiento para la preparacion de derivados peptidicos
DE69327328D1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
ES2153906T3 (es) Uso de incienso para el tratamiento de la enfermedad de alzheimer.
ECSP044986A (es) Composicion farmaceutica que comprende lumiracoxib
ES2119748T3 (es) Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.
ES8400742A1 (es) Procedimiento de preparacion de las dibenzooxepinas sustituidas y de sus sales de adicion con un acido mineral u organi-co.
ES2150907T3 (es) Derivados de aminoacidos.
ES2196000T3 (es) Compuesto de pirroloazepina.
ATE126061T1 (de) Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.
BR9913982A (pt) Derivado de piridil-4h-1,2,4-oxadiazina opticamente ativo e seu uso no tratamento de doenças vasculares
ES2093246T3 (es) Compuestos de benzazepina terapeuticos.
AR007369A1 (es) El uso de derivados carboxilados y un medicamento que contiene uno o mas de dichos derivados
ES2082023T3 (es) Soluciones inyectables listas para su utilizacion que contienen un agente antitumoral del tipo antraciclina glucosido.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 496796

Country of ref document: ES